Effect of oral citrulline supplementation on whole body protein metabolism in adult patients with short bowel syndrome: A pilot, randomized, double-blind, cross-over study.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
12 2019
Historique:
received: 04 06 2018
revised: 27 11 2018
accepted: 26 12 2018
pubmed: 16 1 2019
medline: 22 9 2020
entrez: 16 1 2019
Statut: ppublish

Résumé

As citrulline is produced by small intestine, plasma citrulline concentration is decreased and may become essential in patients with short bowel syndrome (SBS). In a rat model of SBS, citrulline supplementation enhanced muscle protein synthesis. The aim of the study was to determine whether citrulline impacts whole body protein metabolism in patients with SBS. Nine adults with non-malignant SBS (residual small bowel 90 ± 48 cm; mean ± SD) who were in near-normal nutritional status without any artificial nutrition, were recruited long after surgery. They received 7-day oral supplementation with citrulline (0.18 g/kg/day), or an iso-nitrogenous placebo in a randomized, double-blind, cross-over design with a 13-day wash-out between regimens, and an intravenous 5-h infusion of L-[1- Plasma citrulline concentration rose 17-fold (25 ± 9 vs. 384 ± 95 μmol/L) and plasma arginine 3-fold after oral citrulline supplementation (both p < 4 × 10 1) Oral citrulline supplementation enhances citrulline and arginine bioavailability in SBS patients. 2) Oral citrulline supplementation does not have any anabolic effect on whole body protein metabolism in patients with SBS in good nutritional status, in the late phase of intestinal adaptation, and with near-normal baseline citrulline homeostasis. 3) Whether oral citrulline would impact whole body protein anabolism in severely malnourished SBS patients in the early adaptive period, and with baseline plasma citrulline below 20 μmol/L, warrants further study. Registered under ClinicalTrials.gov Identifier no. NCT01386034.

Sections du résumé

BACKGROUND & AIMS
As citrulline is produced by small intestine, plasma citrulline concentration is decreased and may become essential in patients with short bowel syndrome (SBS). In a rat model of SBS, citrulline supplementation enhanced muscle protein synthesis. The aim of the study was to determine whether citrulline impacts whole body protein metabolism in patients with SBS.
METHODS
Nine adults with non-malignant SBS (residual small bowel 90 ± 48 cm; mean ± SD) who were in near-normal nutritional status without any artificial nutrition, were recruited long after surgery. They received 7-day oral supplementation with citrulline (0.18 g/kg/day), or an iso-nitrogenous placebo in a randomized, double-blind, cross-over design with a 13-day wash-out between regimens, and an intravenous 5-h infusion of L-[1-
RESULTS
Plasma citrulline concentration rose 17-fold (25 ± 9 vs. 384 ± 95 μmol/L) and plasma arginine 3-fold after oral citrulline supplementation (both p < 4 × 10
CONCLUSION
1) Oral citrulline supplementation enhances citrulline and arginine bioavailability in SBS patients. 2) Oral citrulline supplementation does not have any anabolic effect on whole body protein metabolism in patients with SBS in good nutritional status, in the late phase of intestinal adaptation, and with near-normal baseline citrulline homeostasis. 3) Whether oral citrulline would impact whole body protein anabolism in severely malnourished SBS patients in the early adaptive period, and with baseline plasma citrulline below 20 μmol/L, warrants further study. Registered under ClinicalTrials.gov Identifier no. NCT01386034.

Identifiants

pubmed: 30642738
pii: S0261-5614(18)32598-6
doi: 10.1016/j.clnu.2018.12.030
pii:
doi:

Substances chimiques

Amino Acids 0
Blood Proteins 0
Citrulline 29VT07BGDA

Banques de données

ClinicalTrials.gov
['NCT01386034']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2599-2606

Informations de copyright

Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Auteurs

Adam Jirka (A)

Nutrition Support Team, Division of Gastroenterology, IMAD, University Hospital, Nantes, France; INRA UMR 1280 PHAN, University of Nantes, IMAD, CRNH-Ouest, France.

Sabrina Layec (S)

Nutrition Department, Clinique St-Yves, Rennes, France.

Denis Picot (D)

Nutrition Department, Clinique St-Yves, Rennes, France.

Silvia Bernon-Ferreira (S)

INRA UMR 1280 PHAN, University of Nantes, IMAD, CRNH-Ouest, France.

Nadège Grasset (N)

INRA UMR 1280 PHAN, University of Nantes, IMAD, CRNH-Ouest, France; Department of Dietetics, University Hospital, Nantes, France.

Laurent Flet (L)

Pharmacy Department, University Hospital, Nantes, France.

Ronan Thibault (R)

INSERM, INRA, Univ Rennes, Nutrition Metabolism and Cancer, NuMeCan, Nutrition Unit, CHU Rennes, Rennes, France.

Dominique Darmaun (D)

Nutrition Support Team, Division of Gastroenterology, IMAD, University Hospital, Nantes, France; INRA UMR 1280 PHAN, University of Nantes, IMAD, CRNH-Ouest, France. Electronic address: ddarmaun@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH